Molycorp's (MCP -11%) ugly day nears a merciful end, capped by a Dahlman Rose downgrade based on...
Molycorp's (MCP -11%) ugly day nears a merciful end, capped by a Dahlman Rose downgrade based on the unanticipated additional scaling up of capital requirements, also noting an additional $130M in capex for 2013. Assuming the proposed $300M capital raise is finalized, 25M new shares are issued and the revised capex, the firm sees a negative ~$1.00/share impact to NAV.
From other sites
at Benzinga.com (Jan 2, 2015)
at CNBC.com (Jul 4, 2014)
at CNBC.com (Jun 16, 2014)
at CNBC.com (Jun 4, 2014)
at CNBC.com (Apr 25, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs